Mark Littlewood quoted by Conservative Home

IEA Director General Mark Littlewood's comments on the Spending Review were included by Conservative Home in a round-up of think tank responses. Mark said: “The Chancellor’s diagnosis was correct – and it is encouraging that he grasps the scale of the problem. The eye of the economic storm has yet to hit. The Covid contraction ... Continue reading

Dr Kristian Niemietz writes for The Telegraph

Anti-capitalism is based on "an emotional, visceral dislike of the market economy, and anti-capitalist arguments are just a post-hoc attempt to rationalise that gut feeling", writes the IEA's Head of Political Economy Dr Kristian Niemietz. Because of this attitude, even when private enterprise saves the day  - such has been the case with Covid vaccines ... Continue reading

Christopher Snowdon writes for CapX

A century after the US began its disastrous experiment with alcohol prohibition, it seems that every generation has to learn the lessons for itself. Prohibition does not prohibit – drinkers keep drinking and smokers keep smoking – but it enriches criminals, robs governments of tax revenue, corrupts institutions and puts people out of work, writes ... Continue reading

Mark Littlewood responds to the Chancellor's party conference speech

In his speech to Conservative Party Conference, Sajid Javid pledged to promote at "infrastructure revolution" but as long as HS2 remains on the government balance sheet "it is near-impossible justify any hike in transport spending”, says the IEA's Director-General Mark Littlewood. Read the full piece here. Read Mark's full response to the Chancellor's speech here.... Continue reading

Christopher Snowdon quoted in the Daily Mail

"Health warnings on salt packets will do nothing for public health and everything to continue infantilising the British public, eroding individual responsibility for what we choose to eat", says Christopher Snowdon, Head of Lifestyle Economics at the Institute of Economic Affairs. Christopher was responding to a group of doctors who have demanded the warnings, suggesting ... Continue reading

Christopher Snowdon writes for The Telegraph

US lawmakers are exploiting a "contrived panic" around vaping to bring in the excessive regulation they have always wanted, argues Christopher Snowdon, Head of Lifestyle Economics at the Institute of Economic Affairs. Writing for the Telegraph online, Christopher says that while the media and the Centre for Disease Control have "played dumb" on acknowledging the ... Continue reading

Len Shackleton quoted in the Daily Express

Labour's plans for a four-day working week would come with significant cost because productivity cannot always be increased, says Professor Len Shackleton, IEA Editorial and Research Fellow. Quoted in the Daily Express, Len noted that "there are about a quarter of public sector jobs where productivity cannot be significantly increased. To maintain services by employing ... Continue reading
The Labour Party, like others, wants to promise voters a utopia - with their conference featuring "wild offers, with little talk of the trade-offs or consequences of so much spending" - but they will fail if they continue to reject the role markets play in improving peoples' lives, says Kate Andrews, Associate Director at the ... Continue reading

Christopher Snowdon quoted by the Mail Online

It is too early to tell if minimum unit pricing has had any positive effect on health, says Christopher Snowdon, Head of Lifestyle Economics at IEA. Responding to new figures from Newcastle University, Christopher said that the research did not "reflect the trends in Scotland under minimum pricing" and that in fact "sales figures show ... Continue reading

Kate Andrews quoted in The Sun

Patients in the UK and across the world will suffer from Labour's plans for a new state-run body to manufacture cheap medicines, says the IEA's Associate Director Kate Andrews. Responding to plans set out in Jeremy Corbyn's speech to Labour Party conference, Kate said "medical patents encourage manufacturers to create new, innovative drugs, which patients ... Continue reading